Fewer Puffs, Fewer Problems? ICER Assesses COPD Drugs Slated for Price Negotiations
-
Mar 13, 2025
A recent Institute for Clinical and Economic Review (ICER) report found that Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) and Breo Ellipta (fluticasone/vilanterol), two chronic obstructive pulmonary disease (COPD) treatments, may have “incremental net health benefits” compared with generic alternatives. Both inhalers are manufactured by GSK and are among the 15 drugs chosen for the second round of Medicare drug price negotiations, which will set new maximum fair prices effective in 2027.
Sarah Emond, ICER’s president and CEO, tells AIS Health that the nonprofit organization could not determine the treatments’ cost-effectiveness because CMS does not disclose the prices it pays for the treatments. However, Emond notes that ICER submitted the findings during the public comment period for the Medicare Drug Price Negotiation Program, which was authorized by the Inflation Reduction Act. And she says that “contributing our expertise to the body of evidence that CMS would consider is almost like a public service.”
Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.